New kidney drug OJR520 enters first human safety tests
NCT ID NCT07235059
First seen Nov 19, 2025 · Last updated May 16, 2026 · Updated 21 times
Summary
This study is the first time the experimental drug OJR520 is being tested in humans. It aims to check the drug's safety and how the body processes it in both healthy volunteers and people with chronic kidney disease. The trial is currently recruiting 112 participants and is in Phase 1.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Novartis Investigative Site
RECRUITINGBerlin, 10117, Germany
-
Quotient Sciences Sea View
RECRUITINGMiami, Florida, 33126, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.